JPRN-UMIN000008995CompletedPhase 4
A multicenter phase IV clinical trial to examine the change of low-grade side effects after switch to Nilotinib from other tyrosine kinase inhibitors. - A multicenter phase IV clinical trial to examine the change of low-grade side effects after switch to Nilotinib from other tyrosine kinase inhibitors.
Tokyo CML Conference0 sites55 target enrollmentStarted: September 27, 2012Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 55
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Patients who receive other therapy than TKI for CML 2) Patients participatinng in other clinical trials 3) Patients with bcr-ablT315I mutation 4) Patients who underwent stem cell transplantation 5) Patients with severe or uncontrolled coexisting illness 6) Patients with active malignancies 7) Patients with acute or chronic diseases in liver, pancreas, or severe kidney dysfunction, which is not atttributable to CML 8) Patients in pregnancy, lactation, or not be consent to control births 9) Patients who are assumed ineligible by the primary investigators or corresponding doctors.
Investigators
Similar Trials
Recruiting
Phase 1
Surgical resection combined with intraperitoneal chemotherapy (CT) is the best treatment for selected patients with Peritoneal Metastases from colon cancer. However, the real role of intraperitoneal CT as a necessary component of this treatment is unknown, despite its proven experimental basis. The main objective of this study is to clarify it, so one group of patients will be treated with surgery + intraperitoneal CT and the other with surgery alone.Surgical resection combined with intraperitoneal chemotherapy (CT) is the best treatment for selected patients with Peritoneal Metastases from colon cancer. However, the real role of intraperitoneal CT as a necessary component of this treatment is unknown, despite its proven experimental basis. The main objective of this study is to clarify it, so one group of patientes will be treated with surgery + intraperitoneal CT and the other with surgery alone.EUCTR2019-004679-37-ESHospital Universitario de Fuenlabrada216
Recruiting
Phase 1
Multicentre Phase IV clinical trial to evaluate the efficacy of hyperthermic intraoperative chemotherapy (HIPEC) with Mitomycin-C after complete surgical debulking in patients with peritoneal metastases of colon cancer.peritoneal metastases of colorectal cancerCTIS2024-512726-28-00Hospital Universitario De Fuenlabrada216
Recruiting
Phase 4
A clinical trial to study the effects of combination drug in patients suffering from Dry Cough associated with sneezing and running nose or throat irritation.CTRI/2022/11/047227Sun Pharma Laboratories Limited
Not yet recruiting
Phase 4
A clinical trial to study the effects of combination drug as substitution therapy in patients suffering from Stable Chronic Heart Failure (CHF) with Systolic Dysfunction or in Patients of Stable Chronic Angina Pectoris.CTRI/2023/01/049086Sun Pharma Laboratories Limited
Active, not recruiting
Phase 1
A phase IV, open, multicentric study to evaluate the immune response to a hepatitis B challenge dose in healthy subjects, 72 to 78 months after they received a primary vaccination course of GSK Biologicals’ Engerix™-B (thiomersal-free 20 µg or preservative-free 10 µg) vaccine, in the primary study HBV-280. - HBV-314 BST: 280Hepatitis B vaccine challenge dose given to subjects, 17 to 21 years of age, to evaluate immune memory to Hepatitis B antigen, approximately 6 years after priming with Hepatitis B vaccine.EUCTR2007-000261-38-BEGlaxoSmithKline Biologicals250